LOS ANGELES, Oct. 31, 2019 /PRNewswire/ --Doheny and UCLA Stein Eye Institutes proudly welcome Kaustabh Ghosh, PhD, to the scientific faculty as Associate Professor in basic science at the UCLA David Geffen School of Medicine. Dr. Ghosh is distinguished as an interdisciplinary researcher with expertise in the fields of vascular inflammation, mechanobiology, bioengineering, and nanomedicine.

"I am tremendously proud and honored to begin this position at Doheny-UCLA," says Dr. Ghosh. "I entered the field of biomedical research from an engineering background, which perhaps gave me a new perspective to see things differently. As a biomedical engineer, it allowed me to think about diseases in a way that a typical biomedical researcher and clinician may not."

Dr. Ghosh states that also as a vascular biologist, one such perspective he was able to successfully introduce was the importance of "stiffness" of blood vessels in disease pathogenesis.

"Doheny will be the ideal place for me to realize the true translational potential for my work as it offers strength and resources in ophthalmic imaging," shares Dr. Ghosh. "Doheny also provides the perfect balance between basic science and clinical research."

He adds, "I look forward to developing strong, collaborative relationships with members of Doheny-UCLA engineering, biomedical sciences and clinical infrastructure. Our goal will be to discover effective treatment strategies from a multidisciplinary approach especially in the area of investigating the role of chronic vascular inflammation, a major determinant of various debilitating conditions including macular degeneration and diabetic retinopathy."

Dr. Ghosh was most recently Associate Professor of Bioengineering at University of California, Riverside (UCR) as well as Participating Faculty in the Division of Biomedical Sciences, Stem Cell Center and the Program in Cell, Molecular and Developmental Biology. The Ghosh Research Group at UCR focused on leveraging the principles of mechanobiology to examine and treat inflammationmediated vascular degeneration associated with diabetic retinopathy and agerelated macular degeneration, the leading causes of vision loss in the diabetic and aging population. In 2016, these studies were supported by two R01 grants from the National Eye Institute (NEI), and a macular degeneration grant from the BrightFocus Foundation. Dr. Ghosh has received numerous awards during his research career, including the Hellman Fellowship and the NIH Postdoctoral Training Grant, and has published 24 peer-reviewed papers in highly-regarded journals that include PNAS, The FASEB Journal, Science, and Nano Letters, among others.

In 2011, prior to joining UCR, Dr. Ghosh was a postdoctoral fellow in the laboratory of Donald Ingber, MD, PhD, part of the Vascular Biology Program at Boston Children's Hospital and Harvard Medical School. In 2006, Dr. Ghosh received his PhD in Biomedical Engineering from Stony Brook University, New York. He obtained his undergraduate degree in Chemical Engineering from National Institute of Technology, Warangal, India in 2001.

Dr. Ghosh's dedication to collaborative research and team building is evident in his numerous and illustrious achievements. His distinguished scientific leadership demonstrates an excellence that will contribute greatly to Doheny Eye Institute's research programs.

About Doheny Eye InstituteFor over 70 years, Doheny Eye Institute has been at the forefront of vision science. From seeking new ways to free blockages that prevent fluid drainage in glaucoma, to replacing retinal cells in age-related macular degeneration, to providing colleagues worldwide with standardized analyses of anatomical changes in the eyes of patients, Doheny clinicianscientists and researchers are changing how people see and also how they think about the future of vision. Please visit doheny.org for more information.

Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best inpatient care, vision research and education. This affiliation combines the strength, reputation and distinction of two of the nation's top eye institutions to advance vision research, education and patient care in Southern California.

CONTACT INFORMATIONMedia Contact:Matthew RabinDirect: (323) 342-7101Email: mrabin@doheny.org

View original content to download multimedia:http://www.prnewswire.com/news-releases/doheny-and-ucla-stein-eye-institutes-welcome-kaustabh-ghosh-phd-to-the-scientific-and-clinical-research-faculty-300949566.html

SOURCE Doheny Eye Institute

More here:
Doheny and UCLA Stein Eye Institutes Welcome Kaustabh Ghosh, PhD, to the Scientific and Clinical Research Faculty - P&T Community

Berlin, Germany and Nevada, USA, October 31, 2019 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the first half of 2019, ending on June 30, 2019, and operative highlights.

During the first half of 2019 we have continued to pass several major milestones and have made significant progress both in the EU with our roll-out strategy and the US with the completion of the first stage in our pivotal clinical US study for the focal ablation of intermediate risk prostate cancer, commented Ben Lipps, CEO of MagForce AG and MagForce USA, Inc. I am steadfast in my belief that by pursuing a strategy of expansion with sustainable partnerships in Europe and providing NanoTherm therapy in the US to patients suffering from prostate cancer, MagForce is well positioned for the future.

Operative Highlights:

Driving forward European roll-out strategy with two additional hospitals offering MagForces NanoTherm therapy for the treatment of brain tumors

In April of 2019, the first hospital outside of Germany, the Independent Public Clinical Hospital No. 4 (SPKS4) in Lublin, Poland, inaugurated its NanoTherm treatment center and is now offering the innovative therapy as an additional treatment option for brain tumor patients from Poland and surrounding countries. The SPSK4 team, led by Prof. Dr. hab. n. med. Tomasz Trojanowski and Prof. Dr. hab. n. med. Radoslaw Rola, have initiated patient treatments for a small Investigator Initiated Trial (IIT) to apply to the Agency for Health Technology Assessment and Tariff System for patient reimbursement of NanoTherm therapy as a supplementary treatment. In addition, private pay treatments with NanoTherm therapy financed by crowd or personal funding are now available. Furthermore, In June, MagForce entered into a cooperation agreement with a further German hospital, the Paracelsus Clinic in Zwickau, where a mobile treatment center has been installed. In the meantime, construction has been completed and, subject to a standard final approval of the competent authority in Germany, the NanoActivator is ready-for-use in the clinic with its renowned neurosurgical team around Prof. Dr. med. habil. Jan-Peter Warnke.

These new cooperations in Germany and Poland cover geographically important regions, and therefore represent another crucial step in MagForces European roll-out strategy. Additionally, the Company continues to see great interest in its therapy from further European countries. In Spain, negotiations with a potential new clinical partner are in an advanced stage, and MagForce is confident to be able to update the market once a cooperation agreement has been successfully concluded. Also, in Italy the Company continues to pursue early stage discussions with specialist clinics.

While a broad geographic coverage to provide greater availability for NanoTherm therapy is at the center of MagForces roll-out strategy, the Company also constantly works to further optimize the therapy and educate medical professionals in its use to provide patients with the best care possible. To this day, 5-years survival rates for patients treated with standard of care have not significantly improved over the last decades and remain very poor at 5 percent. Currently, the best that can be offered applying conventional treatment methods is a modest 14-months overall median survival in patients undergoing maximum safe resection plus adjuvant chemoradiotherapy. Longer survival times are furthermore often limited by a decreased quality of life and to highly selected patient sub-groups with certain favorable prognostic factors. Local tumor ablative treatment modalities, such as NanoTherm therapy, have therefore received increasing interest, as NanoTherm therapy has demonstrated to increase overall median survival to 23.2 months.

In their quest to improve patient care, the neurosurgeons applying NanoTherm therapy for the treatment of brain tumors, continue to find additional strategies to improve efficacy. Prof. Dr. Stummer and his team at the University Hospital of Mnster (UKM) for example, who have been treating brain tumor patients with MagForce's NanoTherm therapy since early 2015, introduced a new nanoparticles application technique called 'NanoPaste' in the clinic in 2016. The method itself and variations thereof are protected by MagForces international patent applications. In previous clinical research, the UKM team demonstrated that a better applicability of heat-focusing nanoparticles around the resection wall after surgical removal of a brain tumor could boost the thermotherapy treatment outcome. In a recent study published in January of 2019 in the Journal of Neuro-Oncology, the team was able to extend the previous findings demonstrating that NanoTherm therapy combined with radiotherapy may result in potent antitumor immune responses leading to long-term stabilization of recurrent GBM patients. The team now plans to further investigate their findings in a prospective study.

MagForce remains committed to providing the highest quality of treatment through ongoing support for physicians. Therefore, the Company announced its newly launched NanoTherm Therapy School in January. NanoTherm Therapy School offers a comprehensive application training series, developed in close collaboration with leading experts in the application of the MagForces therapy and consists of three consecutive modules to certify surgeons in the use of its innovative NanoTherm technology: Module A The Basics; Module B Advanced Course Stereotactic Instillation; and Module C Interaction with New Neurosurgical Techniques. The first session, Module A, took place at the end of January 2019, and was met with great excitement from participants. Building on this success, Module B will be held in Berlin on November 14 and 15. On the Companys website, you will find the program and registration details for the next module in November.

Pivotal US study for a unique focal prostate cancer treatment option completed stage 1; preparations for next study stage initiated

In the US, prostate cancer, is one of the most frequently diagnosed forms of cancer. Fortunately, prostate cancer is treatable, if detected early. Still, there remains an important unmet need for patients who have progressed to the medium-risk stage and for whom the benefits of treatment with current methods come with a significant risk of related side effects. NanoTherm therapy has the potential to significantly change the way prostate cancer is treated, as it allows for a less invasive, less aggressive treatment modality that could cure the cancer or, at a minimum, reduce a patients chances of needing a more aggressive treatment in the future.

The MagForce US pivotal clinical study in the indication of prostate cancer continues to progress well and the Company announced the completion of enrollment, treatment, and the analysis of the results of this first stage. During Stage 1, MagForce USA worked diligently with study investigators, medical technicians and patients, to not only successfully develop a standardized clinical procedure but also demonstrated a favorable safety and tolerability profile.

In summary, Stage 1 of the study has shown the following important successes: Firstly, validation of standardized clinical procedure; secondly, initial findings in this cohort show only minimal treatment-related side effects, which were tolerable and similar to those commonly associated with biopsies; and thirdly, the ablation analysis showed very well defined ablation and cell death in the region of the nanoparticle deposit as we observed with the previous pre-clinical results.

The Stage 1 ablation results also confirm the observations of Knavel and Brace in 2013 that from 42 C to 46 C, irreversible damage occurs, and after 10 minutes, significant necrosis occurs. From 46 C to 52 C, the time to cell death decreases owing to a combination of microvascular thrombosis, ischemia, and hypoxia. By heating from the inside out, as done with focal ablation using the NanoTherm therapy system, minimization of side effects can be achieved. With the encouraging results from Stage 1, MagForce is optimistic that the Company will also be able to successfully manage the treatments in the next stage of the clinical trial. With the high interest in enrollment received from prostate cancer patients and their attending physicians, MagForce is confident to be able to successfully enroll the required number of prostate cancer patients for the last stage of the study.

Results of operations, net assets and financial position

Revenues for the reporting period amounted to EUR 26 thousand compared to EUR 24 thousand in the previous year and resulted mainly from commercial treatments of patients with NanoTherm therapy.

Other operating income amounted to EUR 329 thousand (previous year: EUR 9,199 thousand). The high other operating income in the previous year is attributable to the transfer of shares in MagForce USA, Inc., between group companies, realizing hidden reserves in the amount of EUR 8,769 thousand.

The cost of materials decreased from EUR 364 thousand to EUR 194 thousand which was due in particular to the reduction in expenses for purchased services for the NanoActivators.

Personnel expenses increased to EUR 1,846 thousand (previous year: EUR 1,729 thousand) primarily resulting from the addition of employees in the second half of 2018. Other operating expenses remained at the level of the previous year at EUR 1,608 thousand (previous year: EUR 1,527 thousand).

Consequently, the operating result for the first half of 2019 was negative at EUR 3,610 thousand, whereas the previous year ended with a positive operating result of EUR 5,305 thousand due to the transfer of the shares in MagForce USA, Inc., within the group.

In total, the Company generated a net loss for the period of EUR 4,912 thousand (previous year: net profit of EUR 4,106 thousand)

Cash flows from operating activities amounted to EUR -2,856 thousand (previous year: EUR - 4,009 thousand). The cash outflow from operating activities was derived indirectly from the net loss for the period.

The cash outflows from investing activities amounted to EUR -785 thousand (previous year: EUR - 516 thousand) and related primarily to the contributions made in the reporting period to provide financial support for the subsidiary MT MedTech Engineering GmbH and the completion of the mobile NanoActivator therapy center in Lublin, Poland, as well as the construction of a new mobile NanoActivator therapy center in Zwickau, Germany.

The cash flows from financing activities amounted to EUR 3,325 thousand (previous year: EUR 9,189 thousand) and is mainly attributable to the proceeds from the capital increase from Authorized Capital.

At the end of the reporting period, cash and cash equivalents amounted to EUR 1,178 thousand (December 31, 2018: EUR 1,494 thousand).

Financing transactions of the Company

To improve liquidity and to accelerate the on-going international expansion, the Company executed the following financing measure during the first half of the year.

In June, MagForce AG successfully resolved and completed a capital increase from authorized capital. By issuing 1,176,472 new no-par value bearer shares at a price of EUR 4.25 per share under exclusion of the shareholders' statutory subscription rights, the financing measure has a total volume of EUR 5 million, of which the Company received EUR 1.8 million after the reporting date on July 2, 2019.

The additional capital will primarily be used to accelerate the on-going international expansion of MagForce, in particular in Europe. Based on the highly satisfying treatment results, MagForce expects the European roll-out, combined with reimbursement approval in relevant countries, will significantly speed up revenue generation and profitability of the European business.

Outlook and financial prognosis 2019 and beyond

The outlook for the year 2019, as reported in the 2018 annual report, published on June 20, 2019 was reaffirmed by management.

About MagForce AG and MagForce USA, Inc.MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm, NanoPlan, and NanoActivator are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.comGet to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

DisclaimerThis release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

- End of press release -

Read more:
MagForce AG Publishes Financial Results for the First Half of 2019 and Operative Highlights - BioSpace

PALM BEACH, Florida, Oct. 29, 2019 /PRNewswire/ -- There is much activity in the nanotechnology & nanomedicine markets as new treatments and human clinical trials are growing at a record pace. And these new treatment are hope they could be key to combating viral infections such as, bacteria, viruses, fungi,HBV, hepatitis C, Influenza, HSV, Human papillomavirus and parasites account for approximately 15million deaths worldwide, with acute respiratory infections and human immunodeficiency virus (HIV) being the leading causes. The National Institutes for Health NCBI Center for Biotechnology Information (NCBI) reports: "Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery." Mentioned in today's commentary includes: TG Therapeutics, Inc. (NASDAQ: TGTX), NanoViricides, Inc. (NYSE: NNVC), Matinas BioPharma Holdings, Inc. (NYSE: MTNB), Clovis Oncology, Inc. (NASDAQ: CLVS), Pfizer Inc. (NYSE: PFE).

Nanoparticle-based delivery systems present new opportunities to overcome challenges associated with conventional drug therapies and have therefore attracted enormous interest in the treatment of viral infections. Nanomaterials can be engineered to incorporate conventional antiviral properties with those modifications that are unique to nanosystems (ultra small and controllable size, large surface area to volume ratio, and the ability to tailor the surface with the possibility of multi-functionalization). This is undoubtedly a promising tool for biomedical research and clinical use.

One of the more active companies in the industry includes NanoViricides, Inc. (NYSE American: NNVC). NanoViricides,a leader in nanomedicines with novel platform technology to treat difficult and life-threatening viral diseases, on October 9, 2019 announced that it has initiated bio-analytical studies as part of the required IND-enabling preclinical safety and toxicology studies of NV-HHV-101, moving towards human clinical trials.

The Company has contracted NorthEast BioLab, Hamden CT, to conduct the bio-analytical studies and facilitate the toxicokinetic analyses. These studies and analyses are part of the required general safety and toxicology studies that will go into an Investigational New Drug (IND) Application to the US FDA.

NorthEast BioLab has already performed the bio-analytical assay development and validation and is in the process of determining the concentrations of NV-HHV-101 in blood samples from the general safety and toxicology studies that are required for IND.

The company feels that the market size for its immediate target drugs in the HerpeCide program is variously estimated into Billions to tens of Billions of Dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

NanoViricidesalso released a report this past August that its first drug candidate, NV-HHV-101, is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company reports that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.

The Company has previously found that NV-HHV-101 was safe and well tolerated in non-GLP safety/toxicology studies. The GLP studies are an expanded version of the non-GLP studies, with extended treatment, larger number of subjects, and stringent operational requirements as specified by the current Good Laboratory Practices guidelines for such studies.

Additional studies required for the Safety and Toxicology datasets for filing an IND are in progress.

The Company anticipates advancing NV-HHV-101 into human clinical trials for topical dermal treatment of the shingles rash as the initial indication, assuming that these studies are successful. The Company also continues to evaluate this broad-spectrum drug candidate as well as certain variations based on the same candidate, for the treatment of other herpesviruses, namely HSV-1 cold sores and HSV-2 genital herpes. The market size for its immediate target drugs in the HerpeCide program is variously estimated into billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

In addition, the Company also recently announced that its first clinical drug candidate, NV-HHV-101, for the treatment of the Shingles virus (aka VZV), is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company has reported that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.

NanoViricides' current programs target a potential market opportunity of over $20 Billion. Investors are urged to view an informative video interview with Anil R. Diwan, PhD, President and Executive Chairman, who was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London. Click here to access the video interview.

In other biotech news in the markets this week:

TG Therapeutics, Inc.(NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, announced that the follicular lymphoma (FL) cohort of the UNITY-NHL Phase 2b pivotal trial evaluating single agent umbralisib, the Company's novel, once daily, PI3K delta inhibitor, met the primary endpoint of overall response rate (ORR) as determined by Independent Review Committee (IRC) for all treated patients (n=118) who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent. The results met the Company's prespecified ORR target of 40-50%. Importantly, umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports.

The Company plans to present the data at a future medical conference as well as discuss the data with the U.S. Food and Drug Administration (FDA).

Matinas BioPharma Holdings, Inc.(NYSE AMER: MTNB), a clinical stage biopharmaceutical company, this month announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

"We are extremely pleased to advance clinical development of MAT2203 for the treatment of cryptococcal meningitis," commented Theresa Matkovits, Ph.D., Chief Development Officer of Matinas.

Clovis Oncology, Inc.(NASDAQ: CLVS) this month announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement.

"Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting," said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer.

Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2019 and updated certain components of its 2019 financial guidance.Third-Quarter 2019 Revenues of $12.7 Billion, Reflecting 3% Operational Decline; Excluding the Impact from Consumer Healthcare, Third-Quarter 2019 Revenues were Flat Operationally - See the full financial reporting at: https://finance.yahoo.com/news/pfizer-reports-third-quarter-2019-104500229.html

DISCLAIMER:FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein.FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers.Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc.by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:editor@financialnewsmedia.com -+1(561)325-8757

The rest is here:
Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars - P&T Community

New report on Healthcare Nanotechnology (Nanomedicine) Market 2019 focuses on the growth opportunities, which will help the Healthcare Nanotechnology (Nanomedicine) market to expand operations in the existing markets. Healthcare Nanotechnology (Nanomedicine) market research study is significant for manufacturers in the Healthcare Nanotechnology (Nanomedicine) market, including industry stakeholders, distributors, suppliers, and investors, and it can also help them understand applicable strategies to grow in the Healthcare Nanotechnology (Nanomedicine) market.

In Healthcare Nanotechnology (Nanomedicine) Market Report, Following Companies Are Covered:

Healthcare Nanotechnology (Nanomedicine) Market Report Provides Comprehensive Analysis of:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195

Key Market Trends:

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.

Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.

North America is Expected to Hold the Largest Share in the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.

Reasons for Buying Healthcare Nanotechnology (Nanomedicine) Market Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14099195

Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market Report 2019-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Superphosphate Market 2019 Global Industry Share, Size, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2023

Infusion Pump Market Segmentation 2019-2023 Covers Price, Sales, Revenue, Growth Rate Details by Regions, Types, and Applications

Global Nut Meals Market 2019-2022 Segmentation Based on Product, Application and Region

Global Silicon Wafers Market 2019 Global Industry Size, Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2025

Link:
Comprehensive Study on Healthcare Nanotechnology (Nanomedicine) Market 2019 | Trends, Drivers, Strategies, Applications and Competitive Landscape...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, recently presented data at the American Society of Anesthesiologists (ASA) ANESTHESIOLOGY annual meeting from a Phase I/II clinical trial which showed TLC590 to yield more immediate and long-lasting pain reduction than ropivacaine. In addition, in vivo findings in which TLC590 showed no dose-related toxicity and other preclinical data were recently published in the International Journal of Nanomedicine. TLC590 is a non-opioid, BioSeizer formulation of ropivacaine with the aim to manage postsurgical pain for four to seven days with a single dose, potentially deterring the use of opioids following surgery.

At ANESTHESIOLOGY 2019, which took place October 19-23 at the Orange County Convention Center in Orlando, FL, principal investigator Todd Bertoch, MD, Chief Medical Officer at JBR Clinical Research, a CenExel Clinical Research Center of Excellence, presented findings from a Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study of TLC590 following inguinal hernia repair.

Highlights from the e-poster presentation are as follows:

I am delighted to have had the opportunity to present these fantastic results, said Dr. Todd Bertoch. As a clinical researcher specializing in pain, it is so rewarding to be able to share findings that provide hope for a real, substantive weapon in the war against opioids. Clinicians have been waiting patiently for safe, easily administered, very long acting local anesthetics with a rapid onset. These data suggest that we may have found one.

Results of studies evaluating the release profile of TLC590 in vitro and its pharmacokinetics and anesthetic effect in vivo were recently published in the International Journal of Nanomedicine.

Highlights from the publication article are as follows:

The poster presentation and full text article can be accessed under Publications in the Pressroom section of TLCs website at http://www.tlcbio.com.

About TLC590

TLC590 is a non-opioid, BioSeizer sustained release formulation of ropivacaine designed to prolong the retention time of ropivacaine around the injection site as a drug depot, simultaneously extending its therapeutic period and reducing unwanted systemic exposure. A Phase II, randomized, double-blind, comparator- and placebo-controlled clinical trial to evaluate the safety, pharmacokinetics and efficacy of TLC590 following bunionectomy is ongoing.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD). TLC believes that its deep experience with liposome science allows a combination of onset speed and benefit duration, improving active drug concentrations while decreasing unwanted systemic exposures. TLCs BioSeizer technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX active drug loading technology is designed to alter the systemic exposure of a drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients, and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, without limitation, statements regarding TLCs expectations regarding the clinical development of TLC590, the clinical benefits of TLC590 for postsurgical pain management, the timing, scope, progress and outcome of the clinical trials, and the anticipated timelines for the release of clinical data. Words such as may, believe, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and TLC590 or any of our other product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLCs annual report on Form 20-F for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLCs expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

Read the original here:
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY Annual Meeting and in International Journal of Nanomedicine TLC590 showed...

For senior Hasaan Hayat, a Lyman Briggs student with dual majors in neuroscience and human biology, the opportunity to work in a cutting-edge laboratory as an undergraduate researcher both confirmed his interests in technology and medicine and helped illuminate his career path.

For about a year, Hayat has been contributing to research in the lab of Ping Wang, an affiliate with MSUs Precision Health Program, or PHP. Precision medicine, a component of PHP, is a fairly recent field of biomedicine. This field develops personalized, patient-specific therapies and treatments, often incorporating tools like molecular imaging, nanoparticle technology and artificial intelligence to produce better outcomes for patients.

Through research like that of Wang, tools and technologies can be developed to detect disease sooner and treat it earlier, achieving better outcomes and reducing healthcare costs. PHP at MSU aims to transform the approach to healthcare from reactive to proactive by focusing on disease prediction, prevention and early detection.

Hayat has been interested in technology and human biology for as long as he can remember. After he joined Wangs lab, he became especially intrigued by the use of artificial intelligence, or AI, in the field of precision medicine.

As a child, I only dreamed of working on such technology myself due to its complexity and mass potential, but I also feared it, thanks to dystopian films such asTerminatorandiRobotwhere the sentient machine is always portrayed as the bad guy, he said. However, I find that AI can be a crucial, beneficial tool for analysis and monitoring of patients in a more modern field of medicine, specifically in oncology, radiology and stem-cell transplants.

Researching in Wangs lab has provided Hayat a unique platform to investigate the intersection of technology and biology. One specific study involved the application of deep learning in non-invasive imaging for monitoring tumor response to chemotherapy.

With help from Wang and Moore, Hayat put together an abstract of his work titled, Molecular imaging and analysis of uMUC1 expression levels in response to chemotherapy in an orthotopic murine model of ovarian cancer, and submitted it to the World Molecular Imaging Congress 2019, or WMIC 2019, in Montreal, Canada.

The WMIC 2019 program committee invited Hayat to present this research as an oral presentation, which is a high honor for the attendees. Hayats paper was one of the highest-rated abstracts at the conference and he won the Student Travel Award.

Hayat was grateful and energized by the experience of presenting at an international research conference.

The congress was phenomenal. I was able to hear about some amazing research and innovations in the field of medicine and molecular imaging/biology, he said. Networking with knowledgeable individuals from top institutions all over the world was a highlight of the event, and I am thankful to PHP and MSU for this opportunity.

Hayat was originally drawn to MSU for its many research opportunities, and specifically to Lyman Briggs College, because of its solid foundations in science.

I admire Lyman Briggs for its creative and innovative approach to STEM fields, and its focus on preparing students for success in graduate school, he said. The faculty at Lyman Briggs are very supportive and ensure that students have a clear understanding of core scientific concepts.

As for the future, his work with the Precision Health Program is inspiring him to go to medical school.

I aim to pursue an M.D.-Ph.D. after I graduate, a decision that has been heavily reinforced by the research I am doing at the Precision Health Program, and my mentor and PI, Dr. Wang, who himself is an M.D.-Ph.D. I salute the cutting-edge work that is performed here, he said. In the future, it is a dream and vision of mine to bring novel, innovative therapies and technologies such as AI and nanomedicine to the clinic in order to provide tools for physicians to use and to improve patient outcomes.

Visit link:
Briggs undergrad researcher wins award at international conference - MSUToday

Rizia Bardhan

With a research specialty in nanomedicine and nanophotonics and designing materials that fight diseases using image-guided techniques Rizia Bardhan will join the faculty of the Department of Chemical and Biological Engineering in January, 2020.

Bardhan, who has been hired as a tenured associate professor, comes to Iowa State from Vanderbilt University, where she has been an assistant professor in the Department of Chemical and Biomolecular Engineering since 2012.

Her research focuses on designing nanomaterials that can be activated by external stimuli and then utilize them for biomedical imaging, and image-guided drug delivery and immunotherapies across many disease models, including cancer, neurodegenerative disease and infection. She also develops point of care diagnostics that she is currently applying for early detection of preterm birth in pregnant women. Click here for more on her current research.

Prior to joining the faculty of Vanderbilt University she was a postdoctoral fellow at The Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA.

She received a B.A. in mathematics and chemistry at Westminster College, Fulton, Missouri, in 2005 and a Ph.D. in chemistry at Rice University in 2010 under the guidance of Prof. Naomi Halas, a pioneer in nanophotonics and plasmonics.

In the 2020 spring semester at Iowa State she will teach ChE 381, chemical engineering thermodynamics.

Outside of research and teaching, Bardhan enjoys spending time outdoors with her two sons Elan (3) and Jonah (5), and husband Cary Pint, who is also a new Iowa State University faculty member, joining the Department of Mechanical Engineering in January.

See original here:
New CBE professor Bardhan to bring image-guided techniques to fight against disease College of Engineering News Iowa State University - Iowa State...

New York City, NY: October 23, 2019 Published via (Wired Release) Global Nanomedicine Market Research Reportrepresents the proficient analysis of Nanomedicine industry providing a competitive study of leading market players, market growth, consumption(sales) volume, key drivers and limiting factors, future projections for the new-comer to plan their strategies for business. Further, the report contains the study of Nanomedicine market ups and downs of the past few years and forecasts sales investment data from 2019 to 2028.

The Nanomedicine Report outlining the vitals details which are based on manufacturing region, top players, type, applications and so on will give a transparent view of Industry. The important presence of different regional and local players of Nanomedicine market is tremendously competitive. The Nanomedicine Report is beneficial to recognize the annual revenue of key players, business strategies, key company profiles and their benefaction to the market share.

Download Free Sample Copy of Nanomedicine Market Report:https://marketresearch.biz/report/nanomedicine-market/request-sample

Top Manufacturers Are Covered in This Report:Abbott Laboratories, Ablynx NV, Abraxis BioScience, Inc., Celgene Corporation, Teva Pharmaceutical Industries Limited, GE Healthcare Limited, Merck & Co., Inc., Pfizer Inc., Nanosphere, Inc., Johnson & Johnson Services, Inc.

This research report contains the pictorial representation of important data in the form of graphs, figures, diagrams and tables to make simplified for the users to understand the Nanomedicine market new trends clearly.

Geographically, report on Nanomedicine is based on several regions with respect to Nanomedicine export-import ratio of the region, production and sales volume, share of Nanomedicine market and growth rate of the industry. Major regions included while preparing the report areNorth America, Latin America, Europe, Middle East, Africa, and Asia Pacific.

The leading players in Nanomedicine industry are estimated to ahead on these opportunities to invade the global market. Nanomedicine market size and revenue of key players is assessed using the Bottom-up way.

Reasons for Buying Global Nanomedicine Market Report

* Report provides in-depth study on changing Nanomedicine market dynamics.

* Report offers Pin Point study on distinct factors driving and constraining industry growth.

* Technological innovation in market to study Nanomedicine market growth rate.

* Estimated Nanomedicine market growth depending on the study of historical and the present size of the industry.

Customize Report AndInquiry For The Nanomedicine Market Report:https://marketresearch.biz/report/nanomedicine-market/#inquiry

Report Table of Content Gives Exact Idea about Global Nanomedicine Market Report:

Chapter 1explains Nanomedicine report necessary market surveillance, product price structure, and study, market scope and size forecast from 2019 to 2028. Although, Nanomedicine market activity, factors impacting the growth of business also complete analysis of current market holders.

Chapter 2offers detailing of top manufacturers of Nanomedicine market with their share, sales, and revenue.

Chapters 3, 4, 5studies Nanomedicine report competitive study based on the type of product, their regional sales and import-export study, the annual growth ratio of the market and the coming years study from 2019 to 2028.

Chapter 6offers a detailed analysis of Nanomedicine business channels, Nanomedicine market investors, vendors, Nanomedicine suppliers, dealers, Nanomedicine market opportunities and threats.

This content has been distributed via WiredRelease press release distribution service. For press release service inquiry, please reach us at[emailprotected]

Contact Us:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

Read the original post:
Global Nanomedicine Market To Witness Steady Growth During The Forecast Period 2019-2028 - The State News - BBState

Nanobiotechnology, bionanotechnology, and nanobiology are terms that refer to the intersection of nanotechnology and biology.[1] Given that the subject is one that has only emerged very recently, bionanotechnology and nanobiotechnology serve as blanket terms for various related technologies.

This discipline helps to indicate the merger of biological research with various fields of nanotechnology. Concepts that are enhanced through nanobiology include: nanodevices (such as biological machines), nanoparticles, and nanoscale phenomena that occurs within the discipline of nanotechnology. This technical approach to biology allows scientists to imagine and create systems that can be used for biological research. Biologically inspired nanotechnology uses biological systems as the inspirations for technologies not yet created.[2] However, as with nanotechnology and biotechnology, bionanotechnology does have many potential ethical issues associated with it.

The most important objectives that are frequently found in nanobiology involve applying nanotools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptoid nanosheets, for medical and biological purposes is another primary objective in nanotechnology. New nanotools are often made by refining the applications of the nanotools that are already being used. The imaging of native biomolecules, biological membranes, and tissues is also a major topic for the nanobiology researchers. Other topics concerning nanobiology include the use of cantilever array sensors and the application of nanophotonics for manipulating molecular processes in living cells.[3]

Recently, the use of microorganisms to synthesize functional nanoparticles has been of great interest. Microorganisms can change the oxidation state of metals. These microbial processes have opened up new opportunities for us to explore novel applications, for example, the biosynthesis of metal nanomaterials. In contrast to chemical and physical methods, microbial processes for synthesizing nanomaterials can be achieved in aqueous phase under gentle and environmentally benign conditions. This approach has become an attractive focus in current green bionanotechnology research towards sustainable development.[4]

The terms are often used interchangeably. When a distinction is intended, though, it is based on whether the focus is on applying biological ideas or on studying biology with nanotechnology. Bionanotechnology generally refers to the study of how the goals of nanotechnology can be guided by studying how biological "machines" work and adapting these biological motifs into improving existing nanotechnologies or creating new ones.[5][6] Nanobiotechnology, on the other hand, refers to the ways that nanotechnology is used to create devices to study biological systems.[7]

In other words, nanobiotechnology is essentially miniaturized biotechnology, whereas bionanotechnology is a specific application of nanotechnology. For example, DNA nanotechnology or cellular engineering would be classified as bionanotechnology because they involve working with biomolecules on the nanoscale. Conversely, many new medical technologies involving nanoparticles as delivery systems or as sensors would be examples of nanobiotechnology since they involve using nanotechnology to advance the goals of biology.

The definitions enumerated above will be utilized whenever a distinction between nanobio and bionano is made in this article. However, given the overlapping usage of the terms in modern parlance, individual technologies may need to be evaluated to determine which term is more fitting. As such, they are best discussed in parallel.

Most of the scientific concepts in bionanotechnology are derived from other fields. Biochemical principles that are used to understand the material properties of biological systems are central in bionanotechnology because those same principles are to be used to create new technologies. Material properties and applications studied in bionanoscience include mechanical properties(e.g. deformation, adhesion, failure), electrical/electronic (e.g. electromechanical stimulation, capacitors, energy storage/batteries), optical (e.g. absorption, luminescence, photochemistry), thermal (e.g. thermomutability, thermal management), biological (e.g. how cells interact with nanomaterials, molecular flaws/defects, biosensing, biological mechanisms s.a. mechanosensing), nanoscience of disease (e.g. genetic disease, cancer, organ/tissue failure), as well as computing (e.g. DNA computing)and agriculture(target delivery of pesticides, hormones and fertilizers.[8] The impact of bionanoscience, achieved through structural and mechanistic analyses of biological processes at nanoscale, is their translation into synthetic and technological applications through nanotechnology.

Nano-biotechnology takes most of its fundamentals from nanotechnology. Most of the devices designed for nano-biotechnological use are directly based on other existing nanotechnologies. Nano-biotechnology is often used to describe the overlapping multidisciplinary activities associated with biosensors, particularly where photonics, chemistry, biology, biophysics, nano-medicine, and engineering converge. Measurement in biology using wave guide techniques, such as dual polarization interferometry, are another example.

Applications of bionanotechnology are extremely widespread. Insofar as the distinction holds, nanobiotechnology is much more commonplace in that it simply provides more tools for the study of biology. Bionanotechnology, on the other hand, promises to recreate biological mechanisms and pathways in a form that is useful in other ways.

Nanomedicine is a field of medical science whose applications are increasing more and more thanks to nanorobots and biological machines, which constitute a very useful tool to develop this area of knowledge. In the past years, researchers have done many improvements in the different devices and systems required to develop nanorobots. This supposes a new way of treating and dealing with diseases such as cancer; thanks to nanorobots, side effects of chemotherapy have been controlled, reduced and even eliminated, so some years from now, cancer patients will be offered an alternative to treat this disease instead of chemotherapy, which causes secondary effects such as hair loss, fatigue or nausea killing not only cancerous cells but also the healthy ones. At a clinical level, cancer treatment with nanomedicine will consist on the supply of nanorobots to the patient through an injection that will seek for cancerous cells leaving untouched the healthy ones. Patients that will be treated through nanomedicine will not notice the presence of this nanomachines inside them; the only thing that is going to be noticeable is the progressive improvement of their health.[9]

Nanobiotechnology (sometimes referred to as nanobiology) is best described as helping modern medicine progress from treating symptoms to generating cures and regenerating biological tissues. Three American patients have received whole cultured bladders with the help of doctors who use nanobiology techniques in their practice. Also, it has been demonstrated in animal studies that a uterus can be grown outside the body and then placed in the body in order to produce a baby. Stem cell treatments have been used to fix diseases that are found in the human heart and are in clinical trials in the United States. There is also funding for research into allowing people to have new limbs without having to resort to prosthesis. Artificial proteins might also become available to manufacture without the need for harsh chemicals and expensive machines. It has even been surmised that by the year 2055, computers may be made out of biochemicals and organic salts.[10]

Another example of current nanobiotechnological research involves nanospheres coated with fluorescent polymers. Researchers are seeking to design polymers whose fluorescence is quenched when they encounter specific molecules. Different polymers would detect different metabolites. The polymer-coated spheres could become part of new biological assays, and the technology might someday lead to particles which could be introduced into the human body to track down metabolites associated with tumors and other health problems. Another example, from a different perspective, would be evaluation and therapy at the nanoscopic level, i.e. the treatment of Nanobacteria (25-200nm sized) as is done by NanoBiotech Pharma.

While nanobiology is in its infancy, there are a lot of promising methods that will rely on nanobiology in the future. Biological systems are inherently nano in scale; nanoscience must merge with biology in order to deliver biomacromolecules and molecular machines that are similar to nature. Controlling and mimicking the devices and processes that are constructed from molecules is a tremendous challenge to face the converging disciplines of nanotechnology.[11] All living things, including humans, can be considered to be nanofoundries. Natural evolution has optimized the "natural" form of nanobiology over millions of years. In the 21st century, humans have developed the technology to artificially tap into nanobiology. This process is best described as "organic merging with synthetic." Colonies of live neurons can live together on a biochip device; according to research from Dr. Gunther Gross at the University of North Texas. Self-assembling nanotubes have the ability to be used as a structural system. They would be composed together with rhodopsins; which would facilitate the optical computing process and help with the storage of biological materials. DNA (as the software for all living things) can be used as a structural proteomic system - a logical component for molecular computing. Ned Seeman - a researcher at New York University - along with other researchers are currently researching concepts that are similar to each other.[12]

DNA nanotechnology is one important example of bionanotechnology.[13] The utilization of the inherent properties of nucleic acids like DNA to create useful materials is a promising area of modern research. Another important area of research involves taking advantage of membrane properties to generate synthetic membranes. Proteins that self-assemble to generate functional materials could be used as a novel approach for the large-scale production of programmable nanomaterials. One example is the development of amyloids found in bacterial biofilms as engineered nanomaterials that can be programmed genetically to have different properties.[14]Protein folding studies provide a third important avenue of research, but one that has been largely inhibited by our inability to predict protein folding with a sufficiently high degree of accuracy. Given the myriad uses that biological systems have for proteins, though, research into understanding protein folding is of high importance and could prove fruitful for bionanotechnology in the future.

Lipid nanotechnology is another major area of research in bionanotechnology, where physico-chemical properties of lipids such as their antifouling and self-assembly is exploited to build nanodevices with applications in medicine and engineering.[15]

Meanwhile, nanotechnology application to biotechnology will also leave no field untouched by its groundbreaking scientific innovations for human wellness; the agricultural industry is no exception. Basically, nanomaterials are distinguished depending on the origin: natural, incidental and engineered nanoparticles. Among these, engineered nanoparticles have received wide attention in all fields of science, including medical, materials and agriculture technology with significant socio-economical growth. In the agriculture industry, engineered nanoparticles have been serving as nano carrier, containing herbicides, chemicals, or genes, which target particular plant parts to release their content.[16] Previously nanocapsules containing herbicides have been reported to effectively penetrate through cuticles and tissues, allowing the slow and constant release of the active substances. Likewise, other literature describes that nano-encapsulated slow release of fertilizers has also become a trend to save fertilizer consumption and to minimize environmental pollution through precision farming. These are only a few examples from numerous research works which might open up exciting opportunities for nanobiotechnology application in agriculture. Also, application of this kind of engineered nanoparticles to plants should be considered the level of amicability before it is employed in agriculture practices. Based on a thorough literature survey, it was understood that there is only limited authentic information available to explain the biological consequence of engineered nanoparticles on treated plants. Certain reports underline the phytotoxicity of various origin of engineered nanoparticles to the plant caused by the subject of concentrations and sizes . At the same time, however, an equal number of studies were reported with a positive outcome of nanoparticles, which facilitate growth promoting nature to treat plant.[17] In particular, compared to other nanoparticles, silver and gold nanoparticles based applications elicited beneficial results on various plant species with less and/or no toxicity.[18][19] Silver nanoparticles (AgNPs) treated leaves of Asparagus showed the increased content of ascorbate and chlorophyll. Similarly, AgNPs-treated common bean and corn has increased shoot and root length, leaf surface area, chlorophyll, carbohydrate and protein contents reported earlier.[20] The gold nanoparticle has been used to induce growth and seed yield in Brassica juncea.[21]

This field relies on a variety of research methods, including experimental tools (e.g. imaging, characterization via AFM/optical tweezers etc.), x-ray diffraction based tools, synthesis via self-assembly, characterization of self-assembly (using e.g. MP-SPR, DPI, recombinant DNA methods, etc.), theory (e.g. statistical mechanics, nanomechanics, etc.), as well as computational approaches (bottom-up multi-scale simulation, supercomputing).

Read more:
Nanobiotechnology - Wikipedia

Grand View Research, Inc. Market Research And Consulting.

According to new report published by Grand View Research,The global nanomedicine market size was estimated at USD 138.8 billion in 2016.Demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025, according to a new report by Grand View Research, Inc. Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.

However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.

Full research report on nanomedicine market analysis:http://www.grandviewresearch.com/industry-analysis/nanomedicine-market

U.S. nanomedicine market by products, 2013 2025 (USD Billion)

Further key findings from the report suggest:

Therapeutics accounted for the largest share of market revenue in 2016 owing to presence of nanoemulsions, nanoformulations, or nanodevices

These devices possess the ability to cross biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend is attributive for higher revenue generation

Presence of substantial number of products manufactured through the use of microbial sources can be attributed for the largest share

In-vitrodiagnostics is expected to witness lucrative progress as a result of R&D carried out in this segment

Introduction of nano-enabled biomarkers, vectors and contrast agents with high-specificity and sensitivity are attributive for projected progress

Clinical cardiology is expected to witness the fastest growth through to 2025 owing to development in nano-functionalization and modification of surfaces for increased biocompatibility of implants in treatment of late thrombosis

Moreover, an abundance of research publications and patent filings from European region with a share of about 25% in nanomedicine-related publications is supportive for revenue generation from European economies

Asia Pacific is estimated to witness the fastest growth over the forecast period

Factors responsible include government and regulatory authorities that have implemented a framework to encourage R&D collaborations and framework extension.

Key players operating in this industry include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck

Active expansion strategies are undertaken by a number of the major market entities in order to strengthen their position

North America dominated the industry in 2016, accounting for a 42% of total revenue

Presence of key participants operating in the region are involved in collaborative activities are attributive for the largest share of North America in sector revenue

View more reports of this category by Grand View Research at:http://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the nanomedicine market on the basis of product, application, nanomolecule type, and region:

Nanomedicine Product Outlook (Revenue, USD Billion; 20132025)

Therapeutics

Regenerative medicine

In-vitro diagnostics

In-vivo diagnostics

Vaccines

Nanomedicine Application Outlook (Revenue, USD Billion; 2013 2025)

Clinical Oncology

Infectious diseases

Clinical Cardiology

Orthopedics

Others

Nanomedicine Nanomolecule Type Outlook (Revenue, USD Billion; 2013 2025)

Nanoparticles

Nanoshells

Nanotubes

Nanodevices

Nanomedicine Regional Outlook (Revenue, USD Billion; 2013 2025)

Read Our Blog:Nanomedicine: Nanoparticles-An innovative solution for targeted drug delivery

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: http://www.grandviewresearch.com

Media Contact Company Name: Grand View Research, Inc. Contact Person: Sherry James, Corporate Sales Specialist U.S.A. Email: Send Email Phone: 1-415-349-0058, Toll Free: 1-888-202-9519 Address:28 2nd Street, Suite 3036 City: San Francisco State: California Country: United States Website: http://www.grandviewresearch.com/industry-analysis/nanomedicine-market

See more here:
Nanomedicine Market Size Worth $350.8 Billion By 2025 | CAGR ... - Press Release Rocket

Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 20
http://my.brainshark.com/Nanomedicine-Market-Global-Industry-Analysis-Size-Share-Growth-Trends-and-Forecast-2013-2019-32554938 - Transparency Market Research...

By: Alina Martin

Continue reading here:
Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 20 - Video

Nanomedicine Ethics
Ethics Regarding Nanomedicine Leicester University.

By: sam123george123

View original post here:
Nanomedicine Ethics - Video

Vancouver BC, Oct 09, 2019 -- Precision NanoSystems (PNI) a global leader of innovative solutions for the discovery, development, and manufacture of nanomedicine based gene and cell therapies, small molecule and protein based drugs is pleased to introduce our newest member of the Nanoassemblr Platform: the IgniteTM available October 15, 2019.

The Ignite embodies everything that made the NanoAssemblr family of instruments the go-to platform for developing new Precision and Gene Therapy medicines for over 100 biopharma companies and featured in over 150 publications. said James Taylor, CEO & Co-Founder PNI. The Ignite brings our latest innovations developed for clinical manufacturing to the bench, and paves the way for new nanomedicine approaches to treat cancer, rare disease and infectious disease.

PNIs proprietary NxGenTM scalable continuous-flow microfluidic technology is at the heart of the NanoAssemblr family, using controlled mixing to reproducibly manufacture the highest quality drug products through a single mixer across scales. Ignite enables rapid benchtop scale development of nanoparticle based RNA, DNA, CRISPR, small molecule and protein therapeutics. Optimized drug products are predictably scaled to advanced preclinical and clinical scale with the NxGen technology on the NanoAssemblr BlazeTM and GMP Systems.

As the leading provider of RNA/DNA drug manufacturing, we designed Ignite with the end in mind developing a robust, scalable process from the earliest stage. Enabling researchers to create transformative medicines at the bench scale, said Euan Ramsay, CCO & Co-Founder PNI.

Excerpt from:
Precision NanoSystems to Launch the Revolutionary Ignite - BSA bureau

IgniteEnables Transformative Medicines: Designed with the End in Mind, Designed for the Future, Designed to Maximize Time

Vancouver BC, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Precision NanoSystems (PNI) a global leader of innovative solutions for the discovery, development, and manufacture of nanomedicine based gene and cell therapies, small molecule and protein based drugs is pleased to introduce our newest member of the Nanoassemblr Platform: the Ignite availabe October 15, 2019.

The Ignite embodies everything that made the NanoAssemblr family of instruments the go-to platform for developing new Precision and Gene Therapy medicines for over 100 biopharma companies and featured in over 150 publications. said James Taylor, CEO & Co-Founder PNI. The Ignite brings our latest innovations developed for clinical manufacturing to the bench, and paves the way for new nanomedicine approaches to treat cancer, rare disease and infectious disease.

PNIs proprietary NxGen scalable continuous-flow microfluidic technology is at the heart of the NanoAssemblr family, using controlled mixing to reproducibly manufacture the highest quality drug products through a single mixer across scales. Ignite enables rapid benchtop scale development of nanoparticle based RNA, DNA, CRISPR, small molecule and protein therapeutics. Optimized drug products are predictably scaled to advanced preclinical and clinical scale with the NxGen technology on the NanoAssemblr Blaze and GMP Systems.

As the leading provider of RNA/DNA drug manufacturing, we designed Ignite with the end in mind developing a robust, scalable process from the earliest stage. Enabling researchers to create transformative medicines at the bench scale, said Euan Ramsay, CCO & Co-Founder PNI.

We are hitting the road and showcasing this revolutionary technology in a location near you. Find localWorkshopsor see Ignite and our complete NanoAssemblr Platform at theseconferences in 2019.

About: PNIs proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments,reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology.

Originally posted here:
Precision NanoSystems to Launch the Revolutionary Ignite - GlobeNewswire

Your sneak preview of the future is the slogan of Innovation Origins, and thats just what we will highlight with our Start-up of the Week column. Over the past few days, five start-ups of the day have been featured and on Saturday we will choose the weeks winner.

Innovation Origins presents a Start-up of the Day each weekday

We shall consider various issues such as sustainability, developmental phase, practical application, simplicity, originality and to what extent they are in line with theSustainable Development Goals of UNESCO. They will all pass by here and at the end of the week, the Start-Up of the Week will be announced.

Moreover, our weekly winners may be awarded another prize. Because at the end of each calendar month, our readers, together with the editors of IO, will select the Start-up of the Month!

The way we use medicines is still somewhat primitive. Maybe thats not surprising, because our options are limited when it comes to taking medication. Most organs are well protected from the outside world. Nevertheless, this also means that medicines cannot be administered very effectively. Dosages are therefore often higher than necessary because they have to travel a long way through our bodies.

Sovigo wants to change this through nanotechnology. Their capsules are about 100 nanometres in size, which is 10,000th of a millimeter (!) The main advantage is that this nanomedicine is effective solely at the point where the medication is actually needed. Preliminary results are encouraging for treating intestinal disorders.

Climate change and dwindling agricultural land are major challenges for food and feed production. The supply of animal protein is particularly problematic.

The start-up Blue Planet Ecosystems, based in San Francisco and Vienna, wants to shift pisciculture (fish farming) to computerized container systems. The ecosystem is to be simulated in such a way that nature is able to grow in self-sustaining LARA systems (Land-based Automated Recirculating Aquaculture).

Lara Systeme (c) Blue Planet Ecosystems

This German start-ups drone system has brought a new automation revolution to warehouses. The flying assistants are able to make an inventory of a warehouse on their own by making a kind of digital impression of it. At present, maintaining a warehouse is a time-consuming task. Doks. Innovation promises a time gain of no less than 90% and a cost reduction of 80%. Data collected by the drones are subsequently made available in a proprietary data analysis system. Similar concepts are focused on a single management system as a rule, whereas Doks offers a universal system.

Giving freedom back to people who have limited freedom of movement. Thats the noble goal that former snowboarder Patrick Mayer has committed himself to. Mayer ended up in a wheelchair for a long time himself and personally experienced how winter can throw a spanner in the works. Moving through snow and over ice in a wheelchair or with crutches is just not much fun.

Which is why he came up with Wheelblades, a kind of mini-snowboard that gives more stability to the front wheels. For people on crutches, there is the SafetyFoot, an extra foothold for underneath crutches. And Wheelblades are also suitable for prams, so that you are able to go on a winter hike with your little one without any hassles.

Recharging: it is perhaps the greatest sore point that is associated with electric mobility. Compared to traditional refueling, it takes ages before you can get back on the road. If its up to the Israeli start-up Chakratec, this will soon be a thing of the past. Their kinetic battery fills up about as fast as your diesel tank does. Yet the potential is even greater: the battery has unlimited charging cycles and contains no pollutants.

They are setting their sights on a heroic reputation. A start-up for the benefit of humankind. What makes this mission even more challenging, is that the market in which they have delved into is dominated by Chinese companies. How do you stand out? The solution is simple and difficult at the same time. Come up with something completely new. The result is a kinetic battery with flywheel technology.

A battery can be highly innovative; but without a good charger it is of little use. Chakratec maintains that current infrastructure has been overwhelmed by reality and is suffering from too much red tape. It would be possible to create fast charging stations anywhere, even with a weak network, with the relevant fast charging technology.

The potential of Chakratecs technology has not gone unnoticed. The start-up has already won several awards, including one for best storage technology. They can add another feather in their cap because the favorable prospects for Chakratec make it the Start-up of the Week!

There is a frantic search going on around the world for efficient and sustainable batteries and the subject is also regularly addressed by Innovation Origins. At the beginning of this month, for example, we spoke to the start-up High Performance Battery, which is also trying to bring a new type of smartphone battery onto the market. Or does the future for cars lie with hydrogen technology? We sought answers to that question here in this series.

Innovation Origins is an independent news platform, which has an unconventional revenue model. We are sponsored by companies that support our mission: spreading the story of innovation. Read more here.

On Innovation Origins you can always read articles for free. We want to keep it that way. Have you enjoyed this article so much that you want to contribute to independent journalism? Click here:

Originally posted here:
Start-up of the week: charging your car can be done in minutes - Innovation Origins

The globalinjectable nanomedicines markettouched USD 479.6 million in 2017, and is expected to reach USD 833.9 million by 2025, growing at a CAGR of 7.3% during 20182025.

Source: GMI Research

Major Factors driving the market growth are: Growing incidence of chronic diseases like cancer, cardiovascular diseases, neurological disorders Increasing research & development activities and clinical trials Rising demand and adoption of minimally invasive treatments Rising government and private funding Increasing geriatric population

Growing demand for minimal invasive treatments is driving the Injectable Nanomedicines market. Introduction of innovative and advanced nanotechnology and nanomedicines, especially in the emerging markets with the help of government and private funding would spur the growth of market for the injectable nanomedicines during the forecast period.

Request for Sample Report https://www.gmiresearch.com/report/global-injectable-nanomedicines-market-by-product/sample-request

A paradigm shifts from traditional therapeutics to novel therapeutics using nanomedicines is propelling the overall market as nanomedicines have higher payload capacity, prolonged blood circulation times, reduced toxicity and improved anti-tumour efficacy. Moreover, the application of injectable nanomedicines for some widespread chronic diseases like migraine and depression is also aiding market growth. The use of injectable nanomedicines are found to be efficient, lasting and easy treatment of many chronic cardiovascular and neurological disorders.

Growing incidence rate due to aging demographic patterns and the extension of health insurance coverage in a developing region will support the market growth. Advancements in cancer drug delivery and personalized cancer treatments, effective and safe treatment of medically refractory movement disorders and the need for fast and efficient cardiovascular systems will primarily drive the global injectable nanomedicine market.

The rising pool of patients of chronic diseases and the need for a fast, efficient and long-lasting treatment with minimal invasion procedures will drive the injectable nanomedicines market.-GMI Research

Based on geography, North America held the largest market share in 2017 due to the significantly high rate of incidence of cancer as well as cardiovascular diseases in the region. Currently, the region has a growing demand for rapid research & development of novel nanomedicine in order to address unmet medical needs. Furthermore, favourable reimbursement policies and increasingly growing partnerships between leading enterprises and nanomedicine start-ups is also expected to create growth opportunities. Europe is the second largest market in 2017 and is promising market due to developed healthcare system and rising adoption of nanomedicine in oncology sector. Asia-Pacific is expected to show promising growth in global injectable nanomedicines during 2018-2025 due to the increasing government and private funding for health care infrastructure along with the rising incidence of neurological disorders. Moreover, increasing adoption of nanomedicine for the treatment of cancer, diabetes, cardiovascular diseases and some infectious disease in the Asia-Pacific region would also contribute significantly to the market growth for injectable nanomedicines in the region.

Based on geography, North America held the largest market share in 2017 due to the significantly high rate of incidence of cancer as well as cardiovascular diseases in the region. Currently, the region has a growing demand for rapid research & development of novel nanomedicine in order to address unmet medical needs. Furthermore, favourable reimbursement policies and increasingly growing partnerships between leading enterprises and nanomedicine start-ups is also expected to create growth opportunities. Europe is the second largest market in 2017 and is promising market due to developed healthcare system and rising adoption of nanomedicine in oncology sector. Asia-Pacific is expected to show promising growth in global injectable nanomedicines during 2018-2025 due to the increasing government and private funding for health care infrastructure along with the rising incidence of neurological disorders. Moreover, increasing adoption of nanomedicine for the treatment of cancer, diabetes, cardiovascular diseases and some infectious disease in the Asia-Pacific region would also contribute significantly to the market growth for injectable nanomedicines in the region.

Key takeaways/key essentials: In 2017, the cancer treatment held the major share for the injectable nanomedicines market followed by the cardiovascular diseases segment. High demand and adoption rate for minimally invasive treatments in the recent past. Extended research and development activities are taking place using the injectable nanomedicines regarding the concept of targeted drug delivery system.

Some of the key players operating in the global market for injectable nanomedicines include Merck & Co., Inc., Lupin, Pacira Pharmaceuticals Inc., Celgene Pharmaceutical Co. Ltd., Amgen, Inc., Janssen Biotech Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bausch & Lomb Inc. among others.

Theglobalinjectable nanomedicines markethas been segmented based on product type, indication type and key geographies. Based on the product type, global injectable nanomedicines market has been segmented into liposomes, micelles, nanocrystals and others. Based on indication type, the market has been segmented into cancers, central nervous system diseases, cardiovascular diseases, inflammatory diseases and others.

The research report global injectable nanomedicines market provides in-depth analysis of injectable nanomedicines market, globally, based on product type, indication and major geographies for the forecast period from 2018 to 2025. The report highlights the major market drivers fuelling the growth as well as challenges faced by the market participants. The research report provides market size and forecast for injectable nanomedicines market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

For more details, browse the Table of Contents:https://www.gmiresearch.com/report/global-injectable-nanomedicines-market-by-product/

Early buyers will get customization upto 20% on report

About GMI Research

GMI Research is a market research and consulting firm which provides research-based solutions to business executives and investment professionals so that they can make right business & investment decisions faster based on real facts. We help business leaders through independent fact-based insight, ensuring their business achieve success by beating the competition.

Media Contact

Company Name: GMI RESEARCHContact Person: Media RelationsPhone: +353 1 442 8820Address:Level 1, The Chase Carmanhall Road, Sandyford Industrial EstateCity: DublinState: DublinCountry: IrelandWebsite:www.gmiresearch.com

Originally posted here:
Rising adoption of minimally invasive treatments for chronic disorders across the globe will propel the growth of injectable nanomedicines market...

Global Nanomaterials in Theranostics Market: Overview

The application of theranostics in nanomedicine is a fast emerging paradigm, which involves the use of nanoparticles or nanoscale materials for a variety of diagnostic, imaging, and therapeutic applications. Recent research efforts have been increasingly focused on designing functional nanomaterials for non-invasive imaging of diseases, including bioimaging and biosensing, advanced biomarkers, and targeted delivery of therapeutic drugs. Efforts are also underway for developing highly biocompatible nanoplatforms for various theranostic nanomedicine applications.

Several nanomaterials in theranostics have proven promising for the treatment of chronic and fatal diseases such as cancer, AIDS, and various types of cardiovascular diseases. Adequate surface modifications are being made in a variety of polymeric and inorganic nanoparticles to enhance their conjugation with biomolecules and their interactions with target tissues. As a result, the market is witnessing the development of various classes of nanoscale particles with reduced cytotoxicity and advanced therapeutic applications, improving the quality of life for patients.

The report offers in-depth insights into the key market dynamics, current trends, and recent technological advances in nanomaterials, emerging theranostics applications, lucrative avenues, and competitive dynamics. The research study takes a closer look at several cross-disciplinary researches in drug discovery and highlights major developments in nanomaterials by leading players for expanding theranostics applications.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/nanomaterials-theranostics-market.html

Global Nanomaterials in Theranostics Market: Trends and Opportunities

The rising incidence of chronic and life-threatening diseases, coupled with the need for improving disease detection, and the demand for advanced chemotherapeutic treatments are the key factors propelling the market. The growing potential of clinically translatable nanomaterials in the areas of biological imaging and therapy is anticipated to boost the market. Continuous researches in improving the biocompatibility of a range of nanoparticles, mainly through appropriate surface modification, has fuelled the demand for nanomaterials in theranostics.

In addition, increasing applications of nanoparticles for effective target-specific drug delivery has stimulated their applications in hyperthermia-based cancer treatments, thereby bolstering the demand for nanomaterials in theranostics. Some of the most common classes of nanoparticles used in theranostic applications are gold nanoparticles, mesoporous silica nanoparticles, quantum dots, and nanocrystals. However, lack of favorable regulatory framework, stringent approval requirements, and spiraling developmental costs are some of the key factors likely to hinder the nanomaterials in theranostics market to an extent. Nevertheless, recent partnerships and collaborations between several pharmaceutical and medical devices companies and substantial investments of biotech companies in nanoparticles are expected to unlock abundant opportunities for market players over the forecast period. Furthermore, the application of carbon-based nanoparticles for making a wide range of drug delivery systems is expected to open up lucrative avenues in the coming years.

Global Nanomaterials in Theranostics Market: Regional Outlook

North America is one of the major markets for nanomaterials in theranostics. In the U.S., the theranostic witnesses wide applications in biosensing, bioimaging, and targeted drug delivery. Recent translational researches in the region have expanded the potential of theranostic nanomedicine for a variety of diseases, thereby boosting the nanomaterials in theranostics market. In addition, a robust awareness among patients and clinicians in the efficacy of nanomaterials in theranostics, and aggressive efforts by manufacturers to market their products are expected to catalyze growth. Europe is another prominent market for the demand for nanomaterials in theranostics. The substantial growth of this regional market can be attributed to growing number of product approvals and vast unmet market needs.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1682&source=atm

Asia Pacific is expected to show vast opportunities for numerous manufacturers and vendors. This is attributed to increased focus on R&D activities in nanoparticles, cheap procurement of raw materials, and a rapidly rising patient population pool.

Companies mentioned in the report

Companies vying for a sustained share in the nanomaterials in theranostics market include Abalonyx, Nanomat, Inc. Affymetrix, Aldlab Nanotech, Berkeley Advanced Biomaterials, Inc., ACS Materials, AMAG Pharmaceuticals, Inc., Applied Graphene Materials plc, A.P. Pharma, Inc., Monogram Biosciences Inc., Nanocarrier Co. Ltd., Liquidia Technologies, Inc., and Advanced Proteome.

Leading players are resorting to acquisitions and collaborations to consolidate their positions across major regions.

Major regions analyzed under this research report are: North America Europe Asia Pacific Rest of the World (RoW)

This report gives you access to decisive data such as: Market growth drivers Factors limiting market growth Current market trends Market structure Market projections for the coming years

Key highlights of this report Overview of key market forces propelling and restraining market growth Up-to-date analyses of market trends and technological improvements Pin-point analyses of market competition dynamics to offer you a competitive edge An analysis of strategies of major competitors An array of graphics and SWOT analysis of major industry segments Detailed analyses of industry trends A well-defined technological growth map with an impact-analysis Offers a clear understanding of the competitive landscape and key product segments

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1682&source=atm

Continue reading here:
Nanomaterials in Theranostics Market by Segmentation: Based on Product Application and Region 2016 2024 - Space Market Research

Pharmaceutical Nanotechnology & Nanomedicine Congress 2020

LexisConferencesconsider it a privilege and a matter of great pride to host Conference on Pharmaceutical Nanotechnology & Nanomedicine Congressis to be held at Venice, Italyfor the duration of May 11-12, 2020. On this auspicious occasion, Organizing Committee invites the participants from all over the world to take part in this annual flagship conference with the theme Exploring the Progress of Nanomedicinewith Trending Nanotechnologies. The conference will provide a forum for interaction among attendees on Pharmaceutical Nanotechnology, Development of Nanotechnology-enabled Devices, Micro Fluidics platform for Nano Particle Synthesis, Toxicology and Risk Assessment of Nanomedicine Systems, MedicalNano Devices and Biosensors, Synthesis of Nanoparticles for Drug Delivery, Nanomedicine for Immune System and Cancer Diagnosis & Therapy.

This global meeting will assemble the world leaders in the expanding fields related to Pharmaceutical Nanotechnology & Nanomedicine. It will create an interface among professionals, academic faculty members, Researchers, Nanotech representatives and students, Nanotechnologists, Manufacturing Medical Device and experts in the fields of Nanotechnology. industry practitioners.The Conference will also have a room for companies and/or institutions to present their services, products, revolutions and research results.

Global Market for Nanotechnology products was priced $22.9 billion in 2013 and unanticipated increased to about $26 billion in 2014. This market is await to reach about $64.2 billion by 2019; a compound annual growth rate (CAGR) is 19.8% from 2014 to 2019. The global market for nanotechnology-enabled printing technology was approximate to be at total $14 billion in 2013. The market is anticipate to grow at a compound annual growth rate (CAGR) of 17.7% over the next five years and to total $31.8 billion by 2018.

Details of Nanomedicine Congress 2020

Conference Name

Place

Date

Nanomedicine Congress 2020

Venice, Italy

May 11-12, 2020

Read the rest here:
Nanomedicine Conferences 2019 | Nanotechnology Meetings ...

The Nanomedicine Market is projected to grow at a rate of 12.6 percent by 2026, to reach USD 343.8 billion in 2026 from USD 132.8 billion in 2018.

The latest report, Nanomedicine market enables stakeholders to gain insights into their potential consumers to construct more effective marketing strategies for the forecast period, 2019 to 2026. Most importantly, the document empowers business owners to seek information about potential consumers and where they can find them. Apart from this, the literature sheds light on how major vendors operating in the Nanomedicine market are making the best use of their marketing campaigns. With an exclusive coverage of the top vendors, the study enables business owners to know more about the local market and locate potential consumers.

Request For Free PDF Sample Of This Research Report At: https://www.reportsanddata.com/sample-enquiry-form/1048

Besides, with real-time data available, the research identifies vital information about buyers such as their age, gender, spending power and end-use. This data can also be used to explore additional information about loyal consumers. The recent report on Nanomedicine market lets you understand what the recent market looks like. It helps product owners get a quick view of the potential buyers who is right around the business so that they can meet and better appeal their requirements. In addition, the study gets accurate statistics that can be used to start or expand the business, including the desired geography.

Companies considered and profiled in this market study

Arrowhead Pharmaceuticals, Inc., Nanospectra Biosciences, Inc., AMAG Pharmaceuticals, Bio-Gate AG, Celgene and Johnson & Johnson

Segments covered in the report:

This report forecasts volume and revenue growth at a global, regional & country level, and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2025. For the purpose of this study, Reports and Data have segmented the global Nanomedicine Market on the basis of products, drug delivery system, application and region:

Products (Revenue, USD Billion; 2018-2026)

Drug Delivery System (Revenue, USD Billion; 2018-2026)

Application Outlook (Revenue, USD Billion; 2018-2026)

Regional Outlook (Revenue, USD Billion; 2018-2026)

Purchase Complete Nanomedicine Market Research Report At: https://www.reportsanddata.com/checkout-form/1048

The report not only empowers companies and individuals to understand the key characteristics of the target market but also the communication preferences. The audience can get the estimated size according to the number of sales in a specific region. By offering access to insights about the profit margin the study aims at improving the communication between the companies and potential customers. Armed with all required information on the recent development in the competitive landscape such as a joint venture, collaboration, acquisition and merger and product launch the study enables business owners to build a strong profile of their best buyers.

The market intelligence report on the Nanomedicine market further investigates the demographic as well as behavioural characteristics. Those planning on creating an effective marketing and sales campaign around potential segments are likely to benefit from the research. The extensive document includes a breakdown of all the key geographic characteristics, substitutes, lifestyle categories and marketing communication. Research provides companies and individuals access to data on customer requirements and off-the-shelf information on their spending capacity

The research provides answers to the following key questions:

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/nanomedicine-market

Originally posted here:
Nanomedicine Market: Industry Growth, Competitive Analysis, Future Prospects and Forecast 2026 - Chronicle Voice

United States of America:-The Nanomedicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Nanomedicine market size is expected to gain market growth in the forecast period of 2020 to 2026, with a CAGR of xx% in the forecast period of 2020 to 2026 and will expected to reach USD xx million by 2026, from USD xx million in 2019.

Under COVID-19 Outbreak, how the Nanomedicine Industry will develop is also analyzed in detail in COVID Impact Chapter of this report.

For Better Understanding, Download FREE Sample Copy of Nanomedicine Market Report(Including full TOC, Graphs, Sample Data, and Tables)@ https://www.marketreportexpert.com/report/Nanomedicine/36175/sample

Some of top players influencing the Global Nanomedicine market:

Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology

Note: We can provide market report in regional language too, German/French/Japanese. We have researched the situation of COVID-19 thoroughly and Our new sample has been updated to reflect COVID-19 Impact on industry trends. We also offer a 25% discount.

Market segmentation

Nanomedicine market is split by Type and by Application. For the period 2015-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Majortype, primarily split into

Pharmaceuticals and Healthcare

Major applications/end users, including

Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends.): https://www.marketreportexpert.com/report/Nanomedicine/36175/inquiry

This report examines all the key factors influencing growth of global Nanomedicine market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global Nanomedicine market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

The Nanomedicine market is analysed and market size information is provided by regions (countries).

The key regions covered in the Nanomedicine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Regional analysis is another highly comprehensive part of the research and analysis study of the global Nanomedicine market presented in the report. This section sheds light on the sales growth of different regional and country-level Nanomedicine markets. For the historical and forecast period 2015 to 2026, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Nanomedicine market.

Get Table of Content, Tables, and Figures of Nanomedicine Market Report: https://www.marketreportexpert.com/report/Nanomedicine/36175/tableofcontent

Some of the key questions answered in this report:

What will the market growth rate, growth momentum or acceleration market carries during the forecast period?Which are the key factors driving the Nanomedicine market?What was the size of the emerging Nanomedicine market by value in 2020?What will be the size of the emerging Nanomedicine market in 2026?Which region is expected to hold the highest market share in the Nanomedicine market?What trends, challenges and barriers will impact the development and sizing of the Global Nanomedicine market?What is sales volume, revenue, and price analysis of top manufacturers of Nanomedicine market?What are the Nanomedicine market opportunities and threats faced by the vendors in the global Nanomedicine Industry?

The reports conclusion leads into the overall scope of the Global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the Global Nanomedicine market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email [emailprotected]Web:-https://www.marketreportexpert.com

https://farmingsector.co.uk/

Continued here:
COVID-19 Impact on Nanomedicine Market Size, Latest Trends, Growth and Share 2020 to 2026| Clinical Cardiology, Urology, Genetics, Orthopedics -...